Search

Copyright of Croatian Journal of Infection / Infektoloski Glasnik is the property of Croatian Society for Infectious Diseases and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The most important use of serology in the COVID-19 diagnostics is for determination of the extent of disease in the population. However, immunoassays could represent an additional diagnostic method, especially in patients with exposure history and clinical symptoms compatible with COVID-19 who failed to be confirmed by RT-PCR. We analyzed the preliminary results of six serology tests for the diagnosis of SARS-CoV-2. Three point-of-care lateral flow chromatographic immunoassays (POC): ACRO, AMP and ENCODE and three enzyme immunoassays (ELISA): DiaPro, Vircell and Euroimmun were used. A total of 15 serum samples from COVID-19 patients and 15 serum samples from asymptomatic persons were tested. Time of sampling for COVID-19 patients was 4 - 10 days (N=4), 11 - 19 days (N=6) and 20 - 34 days (N=5) after disease onset. Initially reactive results were confirmed using a virus neutralization test (VNT). In COVID-19 patients (N=15), IgM/IgA positive detection rates were 9/60.0% (ACRO), 11/73.3% (AMP, ENCODE, Euroimmun), 12/80.0% (DiaPro) and 13/86.6% (Vircell). Overall IgG detection rates were 10//66.6% (AMP, Euroimmun) and 11/73.3% (other tests). According to the sampling time, positive detection rates were as follows: a) days 4 - 10: 1/25.0% and 2/50.0% (IgM/IgA and IgG); b) days 11-19: 4/66.6%-6/100% (IgM/IgA), 4/66.6% and 5/83.3% (IgG); c) days 20 - 34: 4/80.0% and 5/100% (IgM/IgA), 5/100% (IgG). One asymptomatic participant tested IgM/IgA positive using ACRO, DiaPro and Vircell was confirmed seropositive using a VNT. In a group of asymptomatic persons detected seronegative using a VNT (N=14), IgM/IgA negative detection rates were 12/85.7% (ACRO), 13/92.8% (DiaPro, Vircell) and 14/100% (AMP, ENCODE, Euroimmun). IgG negative detection rates were 13/92.8% (ACRO) and 14/100% (other tests). ELISA tests showed a higher overall IgM/IgA sensitivity compared to POC tests in patients with COVID-19, while the IgG sensitivity was similar in both POC and ELISA. [ABSTRACT FROM AUTHOR]

Copyright of Croatian Journal of Infection / Infektoloski Glasnik is the property of Croatian Society for Infectious Diseases and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Croatian Journal of Infection / Infektoloski Glasnik is the property of Croatian Society for Infectious Diseases and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Croatian Journal of Infection / Infektoloski Glasnik is the property of Croatian Society for Infectious Diseases and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)